日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer.

一项 I 期临床试验,研究肝动脉内递送 TG6002 与口服 5-氟胞胞嘧啶联合治疗以肝脏转移为主的结直肠癌患者的疗效

West Emma J, Sadoun Alain, Bendjama Kaidre, Erbs Philippe, Smolenschi Cristina, Cassier Philippe A, de Baere Thierry, Sainte-Croix Sophie, Brandely Maud, Melcher Alan A, Ismail Fay, Scott Karen J, Bennett Angela, Banks Emma, Gasior Ewa, Kent Sarah, Kurzawa Marta, Hammond Christopher, Patel Jai V, Collinson Fiona J, Twelves Chris, Anthoney D Alan, Swinson Dan, Samson Adel

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

标准伊匹木单抗与改良伊匹木单抗联合纳武利尤单抗治疗晚期肾细胞癌:一项随机 II 期试验 (PRISM)

Vasudev, Naveen S; Ainsworth, Gemma; Brown, Sarah; Pickering, Lisa; Waddell, Tom; Fife, Kate; Griffiths, Richard; Sharma, Anand; Katona, Eszter; Howard, Helen; Velikova, Galina; Maraveyas, Anthony; Brown, Janet; Pezaro, Carmel; Tuthill, Mark; Boleti, Ekaterini; Bahl, Amit; Szabados, Bernadett; Banks, Rosamonde E; Brown, Joanne; Venugopal, Balaji; Patel, Poulam; Jain, Ankit; Symeonides, Stefan N; Nathan, Paul; Collinson, Fiona J; Powles, Thomas

Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group

前列腺癌治疗引起的骨丢失的评估和管理指南。专家组共识立场声明

Brown, Janet E; Handforth, Catherine; Compston, Juliet E; Cross, William; Parr, Nigel; Selby, Peter; Wood, Steven; Drudge-Coates, Lawrence; Walsh, Jennifer S; Mitchell, Caroline; Collinson, Fiona J; Coleman, Robert E; James, Nicholas; Francis, Roger; Reid, David M; McCloskey, Eugene

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

PRISM方案:一项随机II期临床试验,研究纳武利尤单抗联合交替给药方案的伊匹木单抗一线治疗晚期或转移性肾细胞癌患者的疗效。

Buckley, Hannah L; Collinson, Fiona J; Ainsworth, Gemma; Poad, Heather; Flanagan, Louise; Katona, Eszter; Howard, Helen C; Murden, Geraldine; Banks, Rosamonde E; Brown, Joanne; Velikova, Galina; Waddell, Tom; Fife, Kate; Nathan, Paul D; Larkin, James; Powles, Thomas; Brown, Sarah R; Vasudev, Naveen S

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

向脑肿瘤患者静脉注射溶瘤病毒可使患者对后续的免疫检查点阻断疗法产生免疫启动作用

Samson Adel, Scott Karen J, Taggart David, West Emma J, Wilson Erica, Nuovo Gerard J, Thomson Simon, Corns Robert, Mathew Ryan K, Fuller Martin J, Kottke Timothy J, Thompson Jill M, Ilett Elizabeth J, Cockle Julia V, van Hille Philip, Sivakumar Gnanamurthy, Polson Euan S, Turnbull Samantha J, Appleton Elizabeth S, Migneco Gemma, Rose Ailsa S, Coffey Matthew C, Beirne Deborah A, Collinson Fiona J, Ralph Christy, Alan Anthoney D, Twelves Christopher J, Furness Andrew J, Quezada Sergio A, Wurdak Heiko, Errington-Mais Fiona, Pandha Hardev, Harrington Kevin J, Selby Peter J, Vile Richard G, Griffin Stephen D, Stead Lucy F, Short Susan C, Melcher Alan A